Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management
G Garcia‐Manero - American journal of hematology, 2023 - Wiley Online Library
Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
G Garcia‐Manero, KS Chien… - American journal of …, 2020 - Wiley Online Library
Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …
Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management
G Montalban‐Bravo… - American journal of …, 2018 - Wiley Online Library
Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
H Döhner, A Dolnik, L Tang, JF Seymour, MD Minden… - Leukemia, 2018 - nature.com
Older patients with newly diagnosed acute myeloid leukemia (AML) in the phase 3 AZA-AML-
001 study were evaluated at entry for cytogenetic abnormalities, and a subgroup of patients …
001 study were evaluated at entry for cytogenetic abnormalities, and a subgroup of patients …
TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
TP53 is a key tumor suppressor gene with protean functions associated with preservation of
genomic balance, including regulation of cellular senescence, apoptotic pathways …
genomic balance, including regulation of cellular senescence, apoptotic pathways …
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
Background Hypomethylating agents, such as decitabine, are the standard of care for older
patients with newly diagnosed acute myeloid leukaemia. Single-arm studies have …
patients with newly diagnosed acute myeloid leukaemia. Single-arm studies have …
TET family dioxygenases and the TET activator vitamin C in immune responses and cancer
X Yue, A Rao - Blood, The Journal of the American Society of …, 2020 - ashpublications.org
Vitamin C serves as a cofactor for Fe (II) and 2-oxoglutarate–dependent dioxygenases
including TET family enzymes, which catalyze the oxidation of 5-methylcytosine into 5 …
including TET family enzymes, which catalyze the oxidation of 5-methylcytosine into 5 …
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms
Y Nannya, M Tobiasson, S Sato, E Bernard… - Blood …, 2023 - ashpublications.org
Azacitidine is a mainstay of therapy for myelodysplastic syndrome (MDS)–related diseases.
The purpose of our study is to elucidate the effect of gene mutations on hematological …
The purpose of our study is to elucidate the effect of gene mutations on hematological …
Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature
CF Craddock, AE Houlton, LS Quek, P Ferguson… - Clinical Cancer …, 2017 - AACR
Purpose: Azacitidine (AZA) is a novel therapeutic option in older patients with acute myeloid
leukemia (AML), but its rational utilization is compromised by the fact that neither the …
leukemia (AML), but its rational utilization is compromised by the fact that neither the …
Next generation sequencing in AML—on the way to becoming a new standard for treatment initiation and/or modulation?
M Leisch, B Jansko, N Zaborsky, R Greil, L Pleyer - Cancers, 2019 - mdpi.com
Acute myeloid leukemia (AML) is a clonal disease caused by genetic abberations occurring
predominantly in the elderly. Next generation sequencing (NGS) analysis has led to a …
predominantly in the elderly. Next generation sequencing (NGS) analysis has led to a …